Peter C Taylor, PhD: Nipocalimab Shows Promise in Rheumatoid Arthritis Treatment
Peter C Taylor, PhD, discusses the efficacy and safety of nipocalimab in patients with active rheumatoid arthritis.
Source: hcplive.com
Peterc Taylor News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peterc Taylor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peterc Taylor Today - Breaking & Trending Today
Peter C Taylor, PhD: Complexities of Treatment and Unmet Needs in Rheumatoid Arthritis
Peter C Taylor, PhD, discusses the current treatment landscape in rheumatoid arthritis and the unmet needs of this patient population.
Source: hcplive.com
Janssen's antibody drug shows phase 2 potential in rheumatoid arthritis
The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn). The antibody drug nipocalimab, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, has shown early promise for treating rheumatoid arthritis (RA) in a phase 2a trial.
Source: biopharma-reporter.com
Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
Investegate announcements from Galapagos NV, Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
Source: investegate.co.uk